SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. [OTCBB: MCET], developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company’s unique technologies to manipulate the immune system.
